The DOI matches its Crossref record.
Prospective Phase II Trial of Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Resectable Adenocarcinoma of the Pancreatic Head
Open accessAbstract
Purpose: To test the safety of neoadjuvant chemotherapy for resectable pancreatic cancer. Patients and Methods: Patients with cytologically proven resectable adenocarcinoma of the pancreatic head were eligible for this prospective phase II trial. After confirmation of resectability by contrast-enhanced computed tomography (ceCT), positron emission tomography/CT, laparoscopy, and endoscopic ultrasound, patients received four biweekly cycles of gemcitabine 1,000 mg/m 2 and cisplatin 50 mg/m 2. Thereafter, staging was repeated and patients underwent surgery. Quality of life (QoL) and prealbumin serum levels were determined pre- and postchemotherapy. Follow-up included 3-month CA 19-9 measurements and ceCT after 6, 12, 18, and 24 months. Histologic tumor response was assessed by two scoring systems. Results: Twenty-eight patients entered this study. Adverse effects were mainly gastrointestinal and hematologic, most often mild, and never of grade 4. Twenty-six patients (93%) had resectable cancer on restaging examinations, and the R0 resection rate was 80%. Histologic tumor response and cytopathic effects were documented in 54% and 83% of patients, respectively. On intention-to-treat analysis, disease-free and overall survival were 9.2 months (95% CI, 5.6 to 12.9 months) and 26.5 months (95% CI, 11.4 to 41.5 months) and 9 months (95% CI, 6.99 to 10.1 months) and 19.1 months (95% CI, 15 to 23.1 months) for ductal adenocarcinoma, respectively. QoL improved in two items and was unchanged in all other items. Moreover, prealbumin serum levels significantly improved during chemotherapy (P = .008). Conclusion: Neoadjuvant chemotherapy with gemcitabine and cisplatin is well tolerated and does not impair resectability of pancreatic cancer. Furthermore, it improves the QoL and the nutritional status of affected patients with favorable overall and disease-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Recent progress in pancreatic cancer
Wolfgang, C. L., Herman, J. M., Laheru, D. A., Klein, A. P., Erdek, M. A., Fishman, E. K., & Hruban, R. H. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21190 · Cited by 910
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Adamska, A., Domenichini, A., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071338 · Cited by 610
Versteijne, E., Vogel, J. A., Besselink, M. G., Busch, O. R. C., Wilmink, J. W., Daams, J. G., van Eijck, C. H. J., Groot Koerkamp, B., Rasch, C. R. N., & van Tienhoven, G. (2018) · British Journal of Surgery · doi:10.1002/bjs.10870 · Cited by 519
Truty, M. J., Kendrick, M. L., Nagorney, D. M., Smoot, R. L., Cleary, S. P., Graham, R. P., Goenka, A. H., Hallemeier, C. L., Haddock, M. G., Harmsen, W. S., et al. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000003284 · Cited by 434
Nanomicellar formulations for sustained drug delivery: strategies and underlying principles
Trivedi, R., & Kompella, U. B. (2010) · Nanomedicine · doi:10.2217/nnm.10.10 · Cited by 358
Metadata
- Authors
- Heinrich, S., Pestalozzi, B. C., Schäfer, M., Weber, A., Bauerfeind, P., Knuth, A., & Clavien, P.-A.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-05-20
- Volume
- 26
- Issue
- 15
- Pages
- 2526-2531
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2053932797
- Cited by
- 187
- References
- 0
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prospective Phase II Trial of Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Resectable Adenocarcinoma of the Pancreatic Head. https://app.cochat.ai/papers/10.1200/jco.2007.15.5556
- The paper
- Heinrich, S., Pestalozzi, B. C., Schäfer, M., Weber, A., Bauerfeind, P., Knuth, A., & Clavien, P.-A. (2008). Prospective Phase II Trial of Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Resectable Adenocarcinoma of the Pancreatic Head. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.15.5556
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.